Core Scientific CEO’s Performance‑Based PSU Buy Signals Strong Long‑Term Confidence and Investor Optimism

Insider Activity Spotlight: Core Scientific Inc.

Performance‑Driven Share Surge

On March 31 2026, Chief Executive Officer Sullivan Adam Taylor completed a performance‑based restricted stock unit (PSU) grant that converted into 741,545 shares of Core Scientific’s common stock. The transaction was executed at no cash price; the effective settlement reflects that the company met its aggressive 2025 fiscal‑year performance thresholds. This event signals a bullish stance for shareholders, indicating that executive compensation is tied to long‑term value creation rather than short‑term trading activity. Concurrently, the company withheld 315,307 shares to satisfy tax obligations on the vested PSUs—a routine but noteworthy step that underscores the magnitude of the grant.

CEO’s Transaction Pattern – A Cautious Optimist

Taylor’s historical trading record shows two sizable sales in late January 2026, each of approximately 274,500 shares at $18.79, which reduced his holdings to just over 4.13 million shares. Those sales occurred after a period of significant shareholding and a recent surge in Core’s market valuation, suggesting a strategic divestiture rather than a panic sale. The March 31 PSU buy, contrasted with his earlier sells, indicates a shift toward long‑term commitment: the CEO is now purchasing back into the company’s stock when performance milestones are met, a behavior that aligns with investor expectations of insider confidence. Historically, Taylor’s trades have been executed at or near market price, with minimal price distortion, reflecting a disciplined approach that respects market integrity.

Implications for Investors

The timing of the PSU settlement—just before the company’s annual proxy filing—could boost investor sentiment. A PSU vesting tied to performance metrics such as revenue growth, R&D milestones, or market expansion offers a clear roadmap for future earnings. Combined with the company’s 52‑week high of $23.63 and a strong yearly gain of 126 %, the CEO’s buy signals that leadership believes the stock is undervalued at the current $15.30 close. However, the company’s negative price‑earnings ratio of –18.68 and a 4.78 % weekly decline remind investors that Core remains in a high‑growth, high‑risk niche within information technology, where valuation swings are common.

Company‑Wide Insider Activity Context

While Taylor’s activity dominates the headline, other insiders such as Todd Duchene have shown a mixed buying and selling pattern, reflecting the typical ebb and flow of executive portfolios. The overall insider activity is modest compared to the CEO’s large transactions, reinforcing that Taylor’s moves are the primary signal for the company’s strategic direction. The recent Form 144 notice on April 1 2026, indicating the sale of 140,000 shares by the company itself, further points to a broader capital‑market strategy aimed at liquidity and potential future capital raises.

Forward‑Looking Takeaway

For investors, the confluence of a performance‑based PSU vesting, the CEO’s historical buying‑after‑selling pattern, and the company’s robust year‑to‑date performance suggests a cautiously optimistic outlook. Core Scientific’s focus on core IT and blockchain infrastructure positions it to capitalize on the next wave of digital‑infrastructure demand. Yet, the negative PE ratio and recent price decline warrant vigilance. Monitoring future performance criteria and any additional insider transactions will provide further insight into whether Taylor and his peers remain committed to steering the company through its next growth phase.